Last reviewed · How we verify

low bile acid binding blenderized diet

Boston Children's Hospital · FDA-approved active Small molecule

A specialized blenderized diet formulation that minimizes bile acid binding to reduce enterohepatic circulation and modify lipid metabolism.

A specialized blenderized diet formulation that minimizes bile acid binding to reduce enterohepatic circulation and modify lipid metabolism. Used for Progressive familial intrahepatic cholestasis (PFIC) and related cholestatic liver diseases.

At a glance

Generic namelow bile acid binding blenderized diet
SponsorBoston Children's Hospital
Drug classDietary intervention / Medical food
ModalitySmall molecule
Therapeutic areaGastroenterology / Hepatology / Metabolic disorders
PhaseFDA-approved

Mechanism of action

This dietary intervention is designed to reduce the binding of bile acids in the intestinal lumen, thereby decreasing their reabsorption and increasing fecal excretion. By limiting bile acid reabsorption, the diet may help normalize bile acid metabolism and reduce associated metabolic complications. This approach is particularly relevant for patients with certain cholestatic or metabolic disorders where bile acid accumulation contributes to disease pathology.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: